Klazien Matter-Walstra

All papers authored by Klazien Matter-Walstra

This paper is made freely available by the publisher.

2017 K. Matter-Walstra

, M. Schwenkglenks, K. J. Dedes

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

Download from link.springer.com

This paper was not found in any repository, but could be made available legally by the author.

2016 Klazien Matter-Walstra

, Matthias Schwenkglenks, Stefan Aebi

, Konstantin Dedes, Joachim Diebold, Mario Pietrini, Dirk Klingbiel, Roger von Moos, Oliver Gautschi, Swiss Group for Clinical Cancer Research

A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing

Upload

Christoph Rochlitz, Martin Bigler, Roger von Moos, Jürg Bernhard, Andreas Wicki

, Khalil Zaman, Klazien Matter-Walstra

, Na Kj, Kyung-Jae Na, Sandro Anchisi, Marc Küng, Tamara Rordorf, Daniela Bärtschi, Daniel Rauch, Markus Borner and 8 other authors

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Download from link.springer.com

Klazien Matter-Walstra

, T. Ruhstaller, D. Klingbiel, Matthias Schwenkglenks, K. J. Dedes

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

Upload

O. Gautschi, Q. Li, K. Matter-Walstra

, D. Betticher, M. Frueh, Daniel Rauch, M. Pless, P. Froesch, N. Mach, Adrian Ochsenbein

143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial.

Upload

Matthias Schwenkglenks, Klazien Matter-Walstra

Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments

Upload

K. W. Matter-Walstra

, R. Achermann, R. Rapold, D. Klingbiel, A. Bordoni, S. Dehler, I. Konzelmann, M. Mousavi, K. M. Clough-Gorr, T. Szucs, M. Schwenkglenks, B. C. Pestalozzi

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09)

Upload

Klazien Matter-Walstra

, R. Braun, C. Kolb, Z. Ademi, R. Dummer, B. C. Pestalozzi, Matthias Schwenkglenks

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors

Upload

This paper is available in a repository.

2015 K. Matter-Walstra

, R. Braun, C. Kolb, Z. Ademi, R. Dummer, B. C. Pestalozzi, M. Schwenkglenks

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting

Download from www.zora.uzh.ch

2014 M. Jakovljevic, F. S. Gutzwiller, M. Schwenkglenks, O. Milovanovic, N. Rancic

, M. Varjacic, D. Stojadinovic, A. Dagovic, K. Matter-Walstra

Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols

Download from doi.org

Klazien W. Matter-Walstra

, Rita Achermann, Roland Rapold, Dirk Klingbiel, Andrea Bordoni, Silvia Dehler, Gernot Jundt, Isabelle Konzelmann, Kerri Clough-Gorr, Thomas Szucs, Bernhard C. Pestalozzi, Matthias Schwenkglenks

Download from www.karger.com

Klazien Matter-Walstra

, Dirk Klingbiel, Thomas Szucs, Bernhard C. Pestalozzi, Matthias Schwenkglenks

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Download from www.zora.uzh.ch

M. Joerger, C. Schaer Thuer, D. Koeberle, K. Matter Walstra

, J. Gibbons Marsico, S. Diem, B. Thuerlimann, T. Cerny

Off-label use of anticancer drugs in eastern Switzerland: A population-based prospective cohort study

Download from www.researchgate.net

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

M. Jakovljevic, M. Schwenkglenks, F. Gutzwiller

, O. Milovanovic, N. Rancic

, M. Varjacic, D. Stojadinovic, A. Dagovic, Klazien Matter-Walstra

Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma.

Upload

Aleksandra Kovacevic

, Viktorija Dragojevic-Simic, Nemanja Rancic

, Milena Jurisevic, Florian S. Gutzwiller

, Klazien Matter-Walstra

, Mihajlo Jakovljevic

End-of-life costs of medical care for advanced stage cancer patients

Download from dx.doi.org

2012 Klazien Matter-Walstra

, Markus Joerger, Ursula Kühnel, Thomas D. Szucs, Bernhard Pestalozzi, Matthias Schwenkglenks

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system

Download from doi.org

2010 M. Joerger, M. Früh, K. Matter-Walstra

, U. Kühnel, B. Pestalozzi, T. Szucs, M. Schwenkglenks

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

Download from academic.oup.com

K. J. Dedes, K. W. Matter-Walstra

, P. Brauchli, M. Schwenkglenks, T. D. Szucs, B. C. Pestalozzi

Trastuzumab beyond progression: a cost-utility analysis

Download from dx.doi.org

2009 Konstantin J. Dedes, Klazien Matter-Walstra

, Matthias Schwenkglenks, Bernhard C. Pestalozzi, Daniel Fink, Peter Brauchli, Thomas D. Szucs, L. I. Chap

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation

Upload

2007 Franziska Schoeni-Affolter, Klazien Matter-Walstra

, Marcel Widmer, André Busato

Satisfaction with primary health care in patients with upper respiratory tract infection: a three-level approach

Download from edoc.unibas.ch

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Klazien Matter-Walstra